KBY Biotech Indexv0.0.34
Search
← Pipeline|Mavuderotide

Mavuderotide

Approved
CRI-6003
By Cristalia
Source: Trial-derived·Trials: 2
Modality
Peptide
MOA
PD-L1i
Target
CD47
Pathway
PI3K/AKT
FLWilms
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
~Jan 2021
→ ~Apr 2022
Phase 3
~Jul 2022
→ ~Oct 2023
NDA/BLA
~Jan 2024
→ ~Apr 2025
Approved
Jul 2025
→ Jan 2029
ApprovedCurrent
NCT03139099
2,338 pts·Wilms
2025-07→2027-07·Recruiting
NCT04977659
286 pts·Wilms
2025-10→2029-01·Active
2,624 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2027-07-261.3y awayPh3 Readout· Wilms
2029-01-082.8y awayPh3 Readout· Wilms
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
Approved
Recruit…
Approved
Active
Catalysts
Ph3 Readout
2027-07-26 · 1.3y away
Wilms
Ph3 Readout
2029-01-08 · 2.8y away
Wilms
RecruitingActive|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT03139099ApprovedWilmsRecruiting2338DAS28
NCT04977659ApprovedWilmsActive286PANSS
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-1085PfizerPreclinicalFXIaPD-L1i
LLY-8903Eli LillyPreclinicalCD47HER2
RilulemzoparlimabNovartisPhase 2/3KRASG12DPD-L1i
SNY-9600SanofiNDA/BLAB7-H3PD-L1i
GSK-4334GSKPreclinicalCD47WRNi
NirafutibatinibBayerPhase 2WRNPD-L1i
MotainavolisibAmgenNDA/BLACD47PD-L1i
BNT-8090BioNTechPhase 2AuroraAPD-L1i
MiriglumideAlnylamPhase 3CD3PD-L1i
BMR-1165BioMarinPhase 2CD47TYK2i